Find information and the latest updates and background information on recent events related to a few of our key products.
Updated packaging now available for SANDIMMUNE® 100 mg blister packages
Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in child
Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis
Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS
Novartis Financial Results – Q3 2020
New policy related to the 340B program
AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
Notice to Healthcare Providers and Entities
Novartis Financial Results – Q2 2020
Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies
Novartis Resolves Legacy FCPA Investigations
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
Standing for Racial Equity and Justice as One Novartis
AveXis joins AAVCOVID vaccine program from Massachusetts Eye and Ear and Massachusetts General Hospital
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide
Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial
Novartis is making a strong contribution to the fight against the COVID-19 pandemic
Novartis US response to COVID-19
Corrective Action for Certain 100-mg SANDIMMUNE® and NEORAL® Blister Packages in the US
Novartis provides update on use and safety of Beovu® in patients with wet AMD
Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement
Novartis statement on Zolgensma
The Novartis comment letter submitted July 16, 2018 to the Department of Health and Human Services (HHS) in response to the “HHS Blueprint to Lower Drug Prices and Reduce out-of-Pocket-Costs.”
Novartis response to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs